Cargando…

Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old

BACKGROUND: With infertility populations rapidly aging, treatments improving pregnancy chances assume increasing clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower miscarriage rates in women with diminished ovarian function. This study was plann...

Descripción completa

Detalles Bibliográficos
Autores principales: Tartagni, Massimo, Cicinelli, Maria V, Baldini, Domenico, Tartagni, Mario V, Alrasheed, Hala, DeSalvia, Maria A, Loverro, Giuseppe, Montagnani, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355976/
https://www.ncbi.nlm.nih.gov/pubmed/25884390
http://dx.doi.org/10.1186/s12958-015-0014-3
_version_ 1782360935205175296
author Tartagni, Massimo
Cicinelli, Maria V
Baldini, Domenico
Tartagni, Mario V
Alrasheed, Hala
DeSalvia, Maria A
Loverro, Giuseppe
Montagnani, Monica
author_facet Tartagni, Massimo
Cicinelli, Maria V
Baldini, Domenico
Tartagni, Mario V
Alrasheed, Hala
DeSalvia, Maria A
Loverro, Giuseppe
Montagnani, Monica
author_sort Tartagni, Massimo
collection PubMed
description BACKGROUND: With infertility populations rapidly aging, treatments improving pregnancy chances assume increasing clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower miscarriage rates in women with diminished ovarian function. This study was planned to evaluate whether pretreatment with DHEA may improve in vitro fertilization (IVF) parameters and pregnancy outcomes in infertile women with advanced reproductive age and normal ovarian reserve. METHODS: In this double-blind, randomized, placebo-controlled study, 109 infertile patients aging 36–40 years old were selected to undergo the long protocol IVF. Eight weeks before starting the IVF cycle and during treatment, patients in Group 1 received 75 mg of DHEA once a day; patients in control group (Group 2) received placebo. The primary endpoint of the study was number of clinical pregnancy, live birth and miscarriage rates; secondary endpoint was modification of standard IVF parameters, including stimulation duration (days of rhFSH administration), E2 on HCG-day, endometrial thickness, number of retrieved oocytes, metaphase II oocytes, number of transferred embryos and score of leading embryos transferred. RESULTS: Patients in the DHEA group had a significantly higher live birth rate compared with controls (P < 0.05). Conversely, miscarriage rate was higher for patients in the control group (P < 0.05). CONCLUSIONS: DHEA supplementation may significantly improve IVF outcomes in infertile women with advanced reproductive age and normal ovarian reserve.
format Online
Article
Text
id pubmed-4355976
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43559762015-03-12 Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old Tartagni, Massimo Cicinelli, Maria V Baldini, Domenico Tartagni, Mario V Alrasheed, Hala DeSalvia, Maria A Loverro, Giuseppe Montagnani, Monica Reprod Biol Endocrinol Research BACKGROUND: With infertility populations rapidly aging, treatments improving pregnancy chances assume increasing clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower miscarriage rates in women with diminished ovarian function. This study was planned to evaluate whether pretreatment with DHEA may improve in vitro fertilization (IVF) parameters and pregnancy outcomes in infertile women with advanced reproductive age and normal ovarian reserve. METHODS: In this double-blind, randomized, placebo-controlled study, 109 infertile patients aging 36–40 years old were selected to undergo the long protocol IVF. Eight weeks before starting the IVF cycle and during treatment, patients in Group 1 received 75 mg of DHEA once a day; patients in control group (Group 2) received placebo. The primary endpoint of the study was number of clinical pregnancy, live birth and miscarriage rates; secondary endpoint was modification of standard IVF parameters, including stimulation duration (days of rhFSH administration), E2 on HCG-day, endometrial thickness, number of retrieved oocytes, metaphase II oocytes, number of transferred embryos and score of leading embryos transferred. RESULTS: Patients in the DHEA group had a significantly higher live birth rate compared with controls (P < 0.05). Conversely, miscarriage rate was higher for patients in the control group (P < 0.05). CONCLUSIONS: DHEA supplementation may significantly improve IVF outcomes in infertile women with advanced reproductive age and normal ovarian reserve. BioMed Central 2015-03-09 /pmc/articles/PMC4355976/ /pubmed/25884390 http://dx.doi.org/10.1186/s12958-015-0014-3 Text en © Tartagni et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tartagni, Massimo
Cicinelli, Maria V
Baldini, Domenico
Tartagni, Mario V
Alrasheed, Hala
DeSalvia, Maria A
Loverro, Giuseppe
Montagnani, Monica
Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
title Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
title_full Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
title_fullStr Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
title_full_unstemmed Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
title_short Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
title_sort dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355976/
https://www.ncbi.nlm.nih.gov/pubmed/25884390
http://dx.doi.org/10.1186/s12958-015-0014-3
work_keys_str_mv AT tartagnimassimo dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold
AT cicinellimariav dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold
AT baldinidomenico dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold
AT tartagnimariov dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold
AT alrasheedhala dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold
AT desalviamariaa dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold
AT loverrogiuseppe dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold
AT montagnanimonica dehydroepiandrosteronedecreasestheagerelateddeclineoftheinvitrofertilizationoutcomeinwomenyoungerthan40yearsold